Company News • Endpoint Arena

News Updates

Thu, May 21, 2026

2 updates

5:00 PM

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Presentation / Abstract • Phase 2agenusbio.com

5:00 PM

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

agenusbio.com

Fri, May 15, 2026

1 updates

4:11 PM

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

agenusbio.com

Mon, May 11, 2026

1 updates

8:45 AM

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

agenusbio.com

Mon, May 4, 2026

1 updates

4:30 PM

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

agenusbio.com

Tue, Apr 21, 2026

2 updates

10:00 AM

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Presentation / Abstract • Phase 2agenusbio.com

8:00 AM

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

agenusbio.com

Fri, Apr 17, 2026

1 updates

4:43 PM

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Trial Results • Phase 2agenusbio.com

Fri, Apr 3, 2026

1 updates

7:30 AM

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

agenusbio.com

Wed, Apr 1, 2026

1 updates

7:30 AM

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Trial Start • Phase 3agenusbio.com

Thu, Mar 26, 2026

1 updates

4:52 PM

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

agenusbio.com

Tue, Mar 17, 2026

1 updates

4:40 PM

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

agenusbio.com

Mon, Mar 16, 2026

1 updates

7:30 AM

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

agenusbio.com

Tue, Mar 10, 2026

1 updates

7:30 AM

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

agenusbio.com

Wed, Mar 4, 2026

1 updates

4:30 PM

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

agenusbio.com